Affiliate Disclosure: This page contains affiliate links. We may earn a commission when you sign up — at no additional cost to you. Read our full disclosure.
Pivotal trials, mechanism, contraindications, side effects, dosing — every primary source linked to PubMed.
5 pivotal trialsPubMed-linkedUpdated 2026-05-25
SS
Editorial team
Dr. Sam Saberian · Lead Medical Researcher
Medical review by Alen A. Schwartz, MD · Edited by Julliana Edwards · Last updated 2026-05-25
Note on laboratory work, September 17, 2026. Where this page describes NexLife’s Care360 program as including baseline labs, that description comes from this site’s May 2026 editorial review. On a first-party read of nexlife.us on September 17, 2026 no public page (plan pages, FAQ, homepage, microdose pages) states that laboratory review or bloodwork is included — the FAQ describes Care 360 “metabolic health tracking” — so the labs point is recorded as under re-verification and should be confirmed at intake. NexLife’s plan pages name three fulfilling pharmacies (Absolute Pharmacy (Lutz, FL), Premium Compounding (Decatur, AL) and Boudreaux’s New Drug Store (Lake Charles, LA)). Prices and every other statement on this page are unaffected.
*12-month plan · save $240/yr · flat rate across full 0.25–2.4 mg titration. $125 (6-mo, save $84) · $132 (3-mo, save $21) · $139 (monthly).
Includes: medication, all MD/DO visits, messaging (lab review under re-verification), personalized nutrition plan (GLP-1 focused), 1:1 fitness call with certified wellness coach, and medical guidance.
Klarna & Affirm financing accepted at checkout (FAQ).
Compounded only — no brand-name Wegovy® / Ozempic® / Rybelsus®. Cash-pay with HSA/FSA only — no in-network insurance billing. Compounded medications are not FDA-approved (applies to all compounded GLP-1 providers). Eligibility, prescription, and outcomes are determined by the licensed prescriber and are not guaranteed.
Compounded only — no brand-name Wegovy® / Zepbound®. Cash-pay with HSA/FSA only — no in-network insurance billing. Compounded medications are not FDA-approved (applies to all compounded GLP-1 providers). Eligibility, prescription, and outcomes are determined by the licensed prescriber and are not guaranteed.
Pivotal clinical trials
Below: every randomized trial relevant to semaglutide weight management, type 2 diabetes, cardiovascular outcomes, and kidney outcomes. PMIDs link to PubMed.
STEP-1 trial — Pivotal weight-loss in non-diabetic adults. NEJM 2021, n=1,961, PMID 33567185. 14.9% mean weight loss at 2.4 mg / 68 weeks.
SUSTAIN-6 trial — Cardiovascular safety in type 2 diabetes. NEJM 2016, PMID 27633186. 26% MACE reduction in T2D + high CV risk.
SELECT trial — CV outcomes in non-diabetic adults with overweight/obesity + CVD. NEJM 2023, PMID 37952131. 20% MACE reduction.
FLOW trial — Kidney outcomes in T2D + CKD. NEJM 2024, PMID 38785189. 24% reduction in major kidney/CV events.
Mechanism & pharmacology
Semaglutide is a long-acting GLP-1 receptor agonist with ~7-day half-life enabling weekly subcutaneous dosing. Read the mechanism page →
Safety & contraindications
Boxed warning: thyroid C-cell tumors (rodent studies). Contraindicated in MTC, MEN 2, pregnancy, breastfeeding. Full safety page →
